Do palliative embolization in unresectable, unsalvageable recurrent and metastatic head and neck cancer patients help?


Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 31 08 2020
accepted: 16 11 2020
pubmed: 4 1 2021
medline: 5 8 2021
entrez: 3 1 2021
Statut: ppublish

Résumé

Bleeding from the unsalvageable recurrent and metastatic head and neck cancer is not an uncommon occurrence. It is extremely distressing for the patients and their family members and also to the treating doctors. One of the ways to manage this crisis is by selective embolization of the bleeding vessel. In this retrospective study, we audited the patients with unresectable, unsalvageable recurrent and/or metastatic head and neck cancer who underwent selective (palliative) embolization for bleeding at our institute between Jan 2015 and Nov 2019, and assessed its possible benefit in terms of bleeding free interval achieved. Twenty-six palliative embolization was done during the above mentioned period. The majority were male patients (n = 23, 88.4%) with a median age of 54.5 years. The performance status (PS) of most patients was 2 (n = 15, 57.6%). The most common bleeding vessel was the external carotid artery or one of its branches, most commonly lingual artery (n = 5). The bleeding vessel was identified and embolized with PVA/gel foam/coil/glue. All the procedures were uneventful. Out of 26 patients, 3 patients had another bleeding episode subsequently. Most patients had 20 days to 21 months of bleeding free interval. The cost involved in the procedure was between 400 and 2100 US dollars. Selective embolization is an option to be considered in certain patients with unresectable, unsalvageable recurrent and/or metastatic head and neck cancer, when they present with sudden and massive bleeding to the emergency department, at centres where the facility and expertise for this procedure might be available.

Sections du résumé

BACKGROUND BACKGROUND
Bleeding from the unsalvageable recurrent and metastatic head and neck cancer is not an uncommon occurrence. It is extremely distressing for the patients and their family members and also to the treating doctors. One of the ways to manage this crisis is by selective embolization of the bleeding vessel.
METHODOLOGY METHODS
In this retrospective study, we audited the patients with unresectable, unsalvageable recurrent and/or metastatic head and neck cancer who underwent selective (palliative) embolization for bleeding at our institute between Jan 2015 and Nov 2019, and assessed its possible benefit in terms of bleeding free interval achieved.
RESULTS RESULTS
Twenty-six palliative embolization was done during the above mentioned period. The majority were male patients (n = 23, 88.4%) with a median age of 54.5 years. The performance status (PS) of most patients was 2 (n = 15, 57.6%). The most common bleeding vessel was the external carotid artery or one of its branches, most commonly lingual artery (n = 5). The bleeding vessel was identified and embolized with PVA/gel foam/coil/glue. All the procedures were uneventful. Out of 26 patients, 3 patients had another bleeding episode subsequently. Most patients had 20 days to 21 months of bleeding free interval. The cost involved in the procedure was between 400 and 2100 US dollars.
CONCLUSIONS CONCLUSIONS
Selective embolization is an option to be considered in certain patients with unresectable, unsalvageable recurrent and/or metastatic head and neck cancer, when they present with sudden and massive bleeding to the emergency department, at centres where the facility and expertise for this procedure might be available.

Identifiants

pubmed: 33388992
doi: 10.1007/s00405-020-06505-7
pii: 10.1007/s00405-020-06505-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3401-3407

Informations de copyright

© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 21(Suppl 7):252–261
doi: 10.1093/annonc/mdq453
Pérez Higueras A, SauraLorente P, García Alonso J et al (2009) Diagnosis and treatment of head and neck paragangliomas. Uses of angiography and interventional radiology. ActaOtorrinolaringolEsp 60(Suppl.1):53–67
Pereira J, Phan T (2004) Management of bleeding in patients with advanced cancer. Oncologist 9:561–570
doi: 10.1634/theoncologist.9-5-561
Hume B, Wilcox S (2008) Guidelines on the management of bleeding for palliative care patients with cancer. Yorkshire Palliative Medicine Clinical Guidelines Group. http://www.ycn.nhs.uk . Accessed 25 Aug 2020
Rzewnicki I, Kordecki K, Łukasiewicz A et al (2012) Palliative embolization of hemorrhages in extensive head and neck tumors. Pol J Radiol 77(4):17–21
doi: 10.12659/PJR.883624
Duffis EJ, Gandhi DC, Prestigiacomo CJ et al (2012) Head, neck, and brain tumor embolization guidelines. J NeurointervSurg 4(4):251–255
doi: 10.1136/neurintsurg-2012-010350
Lin S (1994) Arterial embolization leading to fatal cerebral infarction (a case report). ZhonghuaEr Bi Yan HouKeZaZhi 29(4):209–210
Kordecki K, Walecki J, Kołodziejczyk J et al (1998) Preoperative embolisation of juvenile nasopharyngeal angiofibromas. Med SciMonit 4(2):358–361
Mine B, Delpierre I, Hassid S et al (2011) The role of interventional neuroradiology in the management of skull base tumours and related surgical complications. B-ENT 7(Suppl.17):61–66
pubmed: 22338376
Elhammady MS, Wolfe SQ, Ashour R et al (2010) Safety and efficacy of vascular tumor embolization using Onyx: is angiographic devascularization sufficient? J Neurosurg 112(5):1039–1045
doi: 10.3171/2009.7.JNS09351
Brooks B (1930) The treatment of traumatic arteriovenous fistula. South Med J 23:100–106
doi: 10.1097/00007611-193002000-00004
Tadavarthy SM, Moller JH, Amplatz K (1975) Polyvinyl alcohol (Ivalon)—a new embolic material. Am J Roentgenol Radium TherNucl Med 125(3):609–616
doi: 10.2214/ajr.125.3.609
Braak SJ, de Witt CA, Disch FJ et al (2009) Percutaneous embolization on hereditary hemorrhagic telangiectasia patients with severe epistaxis. Rhinology 47(2):166–171
pubmed: 19593974
Wong SJ, Machtay M, Li Y (2006) Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy or chemotherapy alone? J ClinOncol 24:2653–2658
doi: 10.1200/JCO.2005.05.3850
Llorente JL, López F, Suárez V et al (2011) Evolution in the treatment of juvenile nasopharyngeal angiofibroma. ActaOtorrinolaringolEsp 62(4):279–286
Brennan JA, Meyers AD, Jafek BW (1990) Penetrating neck trauma: a 5-year review of literature, 1983–88. Am J Otolaryngol 11(3):191–197
doi: 10.1016/0196-0709(90)90037-V

Auteurs

Nitin Shetty (N)

Department of Interventional Radiology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India.

Nandini Menon (N)

Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, 400012, India.

Shivakumar Thiagarajan (S)

Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, 400012, India. drshiva78in@gmail.com.

Shikar Sawhney (S)

Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, 400012, India.

Suyash Kulkarni (S)

Department of Interventional Radiology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India.

Devendra Chaukar (D)

Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, 400012, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH